Skip to main content
. 2020 May 27;12:1758835920927635. doi: 10.1177/1758835920927635

Figure 1.

Figure 1.

Kaplan–Meier curves of survival in pediatric AML patients with respect to ANXA5 expression. (a, b) Effect of ANXA5 expression on OS and EFS in the no-GO treatment group (n = 95). (c, d) Patients with high ANXA5 expression had significantly prolonged OS and EFS in the GO treatment group (n = 158).

AML, acute myeloid leukemia; EFS, event-free survival; GO, gemtuzumab ozogamicin; OS, overall survival.